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Background: The prevalence of type 2 diabetes (T2D) is increasing worldwide and creating a significant burden on
health systems, highlighting the need for the development of innovative therapeutic approaches to overcome
immune dysfunction, which is likely a key factor in the development of insulin resistance in T2D. It suggests that
immune modulation may be a useful tool in treating the disease.
Methods: In an open-label, phase 1/phase 2 study, patients (N = 36) with long-standing T2D were divided into
three groups (Group A, oral medications, n = 18; Group B, oral medications + insulin injections, n = 11; Group C
having impaired β-cell function with oral medications + insulin injections, n = 7). All patients received one
treatment with the Stem Cell Educator therapy in which a patient’s blood is circulated through a closed-loop
system that separates mononuclear cells from the whole blood, briefly co-cultures them with adherent cord blood-
derived multipotent stem cells (CB-SCs), and returns the educated autologous cells to the patient’s circulation.
Results: Clinical findings indicate that T2D patients achieve improved metabolic control and reduced inflammation
markers after receiving Stem Cell Educator therapy. Median glycated hemoglobin (HbA1C) in Group A and B was
significantly reduced from 8.61% ± 1.12 at baseline to 7.25% ± 0.58 at 12 weeks (P = 2.62E-06), and 7.33% ± 1.02 at
one year post-treatment (P = 0.0002). Homeostasis model assessment (HOMA) of insulin resistance (HOMA-IR)
demonstrated that insulin sensitivity was improved post-treatment. Notably, the islet beta-cell function in Group C
subjects was markedly recovered, as demonstrated by the restoration of C-peptide levels. Mechanistic studies
revealed that Stem Cell Educator therapy reverses immune dysfunctions through immune modulation on
monocytes and balancing Th1/Th2/Th3 cytokine production.
Conclusions: Clinical data from the current phase 1/phase 2 study demonstrate that Stem Cell Educator therapy is
a safe approach that produces lasting improvement in metabolic control for individuals with moderate or severe
T2D who receive a single treatment. In addition, this approach does not appear to have the safety and ethical
concerns associated with conventional stem cell-based approaches.
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Type 2 diabetes (T2D) is a major global health issue,
with prevalence rates exceeding 12.1% of the population
in India, 9.7% in China, and 8.3% in the United States
[1,2]. According to a report from the American Diabetes
Association (ADA, Philadelphia, PA, USA), the total
number of Americans living with diabetes will increase
64% by 2025, and diabetes-related Medicare expen-
ditures will increase by 72% to $514 billion/year. More-
over, diabetes and its associated complications (for
example, cardiovascular diseases, stroke, kidney failure
and poor circulation) markedly decrease the quality of
life, limiting the regular activity and productivity of indi-
viduals with the disease and creating significant eco-
nomic and social burdens [3]. Thus, it is a top priority
to find a cure for T2D. To date, animal and clinical stu-
dies demonstrate that insulin resistance is the key me-
chanism leading to the development and pathogenesis of
T2D, though many factors are known to contribute to
the development and severity of the disease (for exam-
ple, obesity, genetic factors and sedentary lifestyle) [3].
Several medications have been shown to improve the
outcome of T2D treatment through various mechanisms
and act on various organs and tissues. However, safety
concerns limit the utility of known insulin sensitizers. For
example, the peroxisome proliferator-activated receptor-γ
(PPAR-γ) agonists (thiazolidinediones, TZDs) are some of
the major frontline insulin-sensitizing drugs for clinical
treatment of T2D that directly improve insulin sensitivity,
but the risk of adverse effects with long-term use of
these compounds is a safety concern [4,5]. Alternative
approaches are needed.
Increasing evidence reveals that T2D subjects display
multiple immune dysfunctions and chronic metabolic in-
flammation. Specifically, inflammatory cytokines derived
from adipocytes and macrophages promote the deve-
lopment of insulin resistance in T2D through JNK and/
or IKKβ/NF-κB pathways, including changes in the
levels of tumor necrosis factor-α (TNFα), interleukin-1
(IL-1), IL-6, IL-17, monocyte chemoattractant protein-1
(MCP-1), resistin and plasminogen activator inhibitor-1
(PAI-1) [6-10]. Control or reversal of these immune dys-
functions and chronic inflammation may provide an al-
ternative approach for overcoming insulin resistance and
may point to a cure for diabetes. However, the failure of
several recent clinical trials in Type 1 diabetes (T1D)
highlights the challenges we face in conquering the
multiple immune dysfunctions by using conventional
immune approaches in humans [11-13]. Based on pre-
clinical studies in mice and humans [14-17], we have
developed Stem Cell Educator therapy [18], an innova-
tive technology designed to control or reverse immune
dysfunctions. Stem Cell Educator therapy consists of
a closed-loop system that circulates a patient’s bloodthrough a blood cell separator (MCS+, Haemonetics,
Braintree, MA, USA), briefly co-cultures the patient’s
lymphocytes with adherent cord blood-derived multi-
potent stem cells (CB-SCs) in vitro, and returns the edu-
cated lymphocytes (but not the CB-SCs) to the patient’s
circulation [18]. Our initial clinical trial in T1D revealed
that a single treatment with the Stem Cell Educator pro-
vides lasting reversal of immune dysfunctions and allows
regeneration of islet β cells and improvement of meta-
bolic control in subjects with long-standing T1D [18,19].
Here, we explore the therapeutic potential of Stem Cell
Educator therapy in T2D subjects.
Methods
Patients
T2D subjects receiving care through the Section of
Endocrinology at the General Hospital of Jinan Military
Command (Jinan, Shandong, China) were enrolled in a
phase 1/phase 2, open-label clinical trial conducted from
August 2011 through September 2012. With oversight
from a planning committee, the principal investigator
designed the trial and received ethical approval for the
clinical treatment protocol and consent from the Ge-
neral Hospital of Jinan Military Command. Written in-
formed consent was obtained from each participant. All
subjects receiving Stem Cell Educator therapy had been
treated with diet, exercise, oral medications and/or insu-
lin injections at stable doses for at least six months prior
to treatment. Key exclusion criteria included clinically
significant liver, kidney or heart disease; pregnancy; im-
munosuppressive medication; viral diseases; or diseases
associated with immunodeficiency; or any other clini-
cally significant, coexisting conditions.
Stem Cell Educator therapy and follow-up
In an open-label, phase 1/phase 2 study, patients (N = 36)
with long-standing T2D were divided into three groups
(Group A, oral medications, n = 18; Group B, oral medica-
tions + insulin injections, n = 11; and Group C having im-
paired islet β cell function with oral medications + insulin
injections, n = 7). Thirty-six participants received a single
treatment with the Stem Cell Educator (Tianhe Stem Cell
Biotechnology®). The preparation of CB-SC cultures and
Stem Cell Educators were performed as previously de-
scribed [18]. Briefly, a 16-gauge IV needle was placed in
the left (or right) median cubital vein, and the patient’s
blood was passed through a blood cell separator MCS+
(Haemonetics®, Braintree, MA, USA) for six to seven
hours to isolate mononuclear cells in accordance with the
manufacturer’s recommended protocol. The collected
mononuclear cells were transferred into the device for ex-
posure to allogeneic CB-SCs. CB-SC-treated mononuclear
cells were returned to the patient’s circulation via a dorsal
vein in the hand with physiological saline. The whole
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scheduled 4, 12, 24, 40 and 56 weeks after treatment for
clinical assessments and laboratory tests. Previous work
demonstrated that participants receiving sham therapy
failed to show changes in immune modulation and
metabolic control [18]. Thus, the main outcome mea-
sures in current trial were changes in glycated hemoglobin
(HbA1C) values, islet β-cell function of T2D, and immune
markers between baseline and follow-up.
Efficacy measurements in metabolic control
To determine the insulin sensitivity, we used fasting
plasma C-peptide instead of fasting insulin for homeosta-
sis model assessment of insulin resistance (HOMA-IR)
and pancreatic islet β-cell function (HOMA-B) analysis,
because 1) C-peptide is a by-product of insulin synthesis
and released at equal levels and 2) T2D patients received
external insulin injections and other treatments that limit
the accuracy of HOMA-IR [20,21]. HOMA-IR c-pep was
calculated using the equation [20-22]: HOMA-IR c-pep =
FPG (mmol/L) × FPC (pmol/L)/22.5. FPG is the value of
fasting plasma glucose. FPC is the value of fasting plasma
C-peptide. The denominator of 22.5 is a normalizing
factor [20]. HOMA-B was calculated using the equa-
tion [21,22]: HOMA-B c-pep = 20 × FPC (pmol/L)/
(FPG (mmol/L)-3.5).
Study end points
The primary study end points were feasibility and safety
of the Stem Cell Educator therapy through 12 weeks
post-treatment and preliminary evaluation of the efficacy
of the therapy for change in HbA1C values of T2D
through 12 weeks compared to baseline. Pancreatic islet
β cell function was assessed by measuring basal and
glucose-stimulated C-peptide production over time, as
described elsewhere [23,24]. Metabolic control was mon-
itored throughout the study. The secondary study end
point was preliminary evidence for efficacy of the ther-
apy in anti-inflammation. Baseline blood samples were
collected prior to Stem Cell Educator therapy.
Flow analysis
Flow analysis was performed as previously described
[16]. For cell surface staining, cells were incubated with
mouse anti-human monoclonal antibodies (eBioscience,
San Diego, CA, USA), including fluorescein isothiocyan-
ate (FITC)-conjugated CD80, phycoerythrin (PE)-conju-
gated CD86, AF 647-conjugated CD14. For intracellular
cytokine staining, cells were initially stained for cell sur-
face antigens (for example, phycoerythrin (PE)-conju-
gated CD4, FITC-conjugated CD25) and then prepared
by using a BD Cytofix/Cytoperm Fixation/Permeabi-
lization kit (BD Biosciences, San Jose, CA, USA). Subse-
quently, cells were stained with different combinationsof antibodies, including FITC-conjugated IL-4, PE-
conjugated IL-5, PE-conjugated IL-12, FITC-conjugated
IL-13 and FITC-conjugated IL-17A (eBioscience), and
Alexa Fluor 647-conjugated anti-Foxp3 (BD Bioscien-
ces). Cells were regularly stained for 45 minutes at 4°C
and then washed with cold PBS prior to flow analysis.
After staining, cells were analyzed using a Cytomics™ FC
500 (Beckman Coulter, Brea, CA, USA) or CyAn ADP
(Beckman Coulter, Brea, CA, USA). Isotype-matched rat
anti-mouse IgG antibodies (eBioscience) served as a
negative control.
Cytokine assay and ELISA
To prepare for cytokine assay, plasma samples were col-
lected from all subjects before and after (one month) re-
ceiving Stem Cell Educator therapy, and kept at −80°C
in a refrigerator. To determine cytokine levels, human
plasma samples were quantified using commercial
ELISA kits following the manufacturer’s instructions.
We purchased human IL-1, IL-6, IL-10, TNFα and TGF-
β1 ELISA kits from Biolegend, Inc. (San Diego, CA,
USA).
Western blot
CB-SCs were collected and solubilized with Complete
Lysis-M buffer with a cocktail of protease inhibitors
(Roche Applied Science, Indianapolis, IN, USA). Cell
samples (20 μg protein each) were mixed with a loading
buffer (62.5 mM Tris–HCl (pH 6.8), 2% SDS, 10% gly-
cerol, 50 mM dithiothreitol (DTT), 2 mg of bromphenol
blue) in a volume ratio of 1:1, boiled, loaded and sepa-
rated by electrophoresis on 10% SDS gel (Bio-Rad,
Hercules, CA, USA). The separated proteins were then
transferred to a nitrocellulose membrane, blocked with
5% non-fat dry milk in Tris-buffered saline with Tween
(TBST) for one hour and incubated with different anti-
bodies: including rabbit anti-human cellular inhibitor of
apoptosis protein (cIAP) 1 and cIAP2 monoclonal an-
tibodies (Abcam, Cambridge, MA, USA) and mouse
anti-human TNF-RI or TNF-RII monoclonal antibodies
(R&D Systems, Minneapolis, MN, USA) at 1:1,000
dilution, diluted in PBST for two hours at room tempe-
rature. After washing, the blot was exposed to a horserad-
ish peroxidase-conjugated secondary antibody (1:2,000;
Thermo Scientific, Pierce Antibodies, Rockford, IL USA)
in PBS-T. The immunocomplexes were visualized by the
enhanced chemiluminescence (ECL, GE Healthcare,
Waukesha, WI, USA) method. Beta-actin served as an
internal loading control.
TNFα treatment and cell proliferation
To determine the effects of TNFα on the proliferation of
CB-SCs, CB-SCs were treated with recombinant human
TNFα (R&D Systems) at different doses, such as 100, 50,
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well plates at 37°C, 8% CO2 conditions. After three days,
cell proliferation was evaluated using a CyQUANTR Cell
Proliferation Assay Kit (EMD Millipore Corporation,
Billerica, MA, USA) [25]. Cell fluorescence was mea-
sured using a Synergy HT Multi-Detection microplate
reader (Bio-Tek Instruments Inc., Winooski, VT, USA)
equipped with filters for 480 nm excitation and 520 nm
emission. The optical values were analyzed using the
manufacturer’s software KC4 v3.1.Cell sorting and co-cultures
To purify CD14+ monocytes, the freshly-isolated periph-
eral blood mononuclear cells (PBMC) were initially in-
cubated with 2.5% horse serum to block Fc receptor
binding and then incubated with FITC-conjugated CD14
(eBiosciences) antibody for 45 minutes at 4°C and
subjected to cell sorting using MoFlo (Beckman Coulter,
Brea, CA, USA). After confirming the purity of the
population (>98%), CD14+ monocytes were collected
and used in different in vitro co-culture experiments
with CB-SCs. Culture of CB-SCs were performed as pre-
viously described [18]. Purified CD14+ monocytes were
co-cultured with CB-SCs at a ratio of 1:5 of CB-SCs:mo-
nocytes. After co-culture with CB-SCs for 18 hours, floa-
ted cells were collected for apoptotic assay (eBiosciences)
by flow cytometry.
To determine the molecular mechanisms underlying
the interaction between CB-SCs and monocytes, bloc-
king experiments with TNF-RI mAb, TNF-RII mAb and
inducible nitric oxide synthase (iNOS) inhibitor 1400W
were performed as previously described [15]. Before co-
culture with CB-SCs, monocytes were initially stimulated
with lipopolysaccharide (LPS, 10 μg/ml) stimulation for
8 hours, and then seeded onto CB-SCs in regular culture
medium at a ratio of 1:5 of CB-SCs:monocytes for 48 hrs
in the presence or absence of 1400W (100 nM). To
block the action of TNF-RI and TNF-RII, the functional
grade purified anti-human TNF-RI and TNF-RII mono-
clonal antibodies (R&D Systems) were administrated at
20 μg/ml in 0.1% BSA/PBS buffer. The 0.1% BSA/PBS
buffer-treated wells served as controls. After incubation
with CB-SCs at 37°C for two hours, cells were washed
with PBS to remove the unused antibodies. The sorted
CD14+ T cells (1 × 105 cells/ml/well) were seeded onto
the TNF-RI or TNF-RII antibody-treated wells in dupli-
cate. To block the action of iNOS and nitric oxide (NO)
production, CB-SCs were pre-treated with 1400W (100
nM, Sigma-Aldrich, St. Louis, MO, USA) for 2 hrs, and
then co-cultured with LPS-stimulated monocytes for 48
hrs, followed by real time PCR analysis by using Human
Th17 for Autoimmunity and Inflammation PCR Array
kit (SABiosciences, Valencia, CA, USA).Statistical analysis
An intention-to treat approach was used, with 36 pa-
tients undergoing Stem Cell Educator therapy. All pa-
tients were included in the safety analyses. The primary
efficacy end point was the change in HbA1C between
baseline and follow-up, with an absolute difference in
HbA1C level of at least 0.5% from baseline.
Results
Feasibility and safety of Stem Cell Educator therapy in
T2D
Baseline characteristics of participants with T2D are pro-
vided in Table 1. Thirty-six patients with T2D have re-
ceived Stem Cell Educator therapy in a safety study, and
their results are similar to the safety evaluation with
T1D participants [18]. No participants experienced any
significant adverse events during the course of treatment
and post-treatment for over a year. Patient complaints
were limited to mild discomfort during venipunctures at
the site of median cubital vein and some soreness of the
arm that resolved quickly following aphaeresis.
Efficacy outcomes in improving metabolic control
After receiving Stem Cell Educator therapy and being
discharged from the hospital, patients continued their
regular medications. Follow-up studies demonstrated
that the median glycated hemoglobin (HbA1C) in Group
A (n = 18) and Group B (n = 11) was significantly
lowered from 8.61% ± 1.12 at baseline to 7.9% ± 1.22 at
4 weeks post-treatment (P = 0.026), 7.25% ± 0.58 at 12
weeks post-treatment (P = 2.62E-06) (Figure 1A), and
7.33% ± 1.02 at one-year post-treatment (P = 0.0002).
According to the A1C goal (<7%) recommended by the
American Diabetes Association (ADA) for the treatment
of adult diabetics, 28% (5/18) of subjects in Group A,
36% (4/11) of subjects in Group B, and 29% (2/7) of sub-
jects in Group C achieved this goal at 12 weeks post-
treatment. More than 31% of total subjects achieved and
maintained the <7% standard for over a year. Addition-
ally, based on the efficacy criteria, 11 of 18 (61.1%) sub-
jects in Group A, 8 of 11 (72.7%) subjects in Group B,
and 4 of 7 (57.1%) subjects in Group C had a reduction
of A1C value (>0.5%) at four weeks post-treatment.
Thirteen of 18 (72.2%) subjects in Group A, 9 of 11
(81.8%) subjects in Group B, and 6 of 7 (85.7%) subjects
in Group C had a reduction of A1C value (>0.5%).
Twenty-eight of 36 (78%) of the total subjects decreased
A1C levels by 1.28 ± 0.66 at 12 weeks post-treatment.
The data demonstrate that glycemic control was improved
in T2D patients after Stem Cell Educator therapy.
To explore the change in insulin sensitivity, we ana-
lyzed HOMA-IR by the product of fasting plasma glu-
cose and C-peptide (instead of insulin due to subjects
receiving insulin injections) in Group A and B. The data
Table 1 Characteristics of the T2D subjects before treatment
Patient no. Age Gender Marriage History (year) BMI Fasting glucose HbA1C (%) C-peptide (ng/ml)*
Group A: Long-standing patients having normal β cell function with oral medications
1 60 M Yes 13 30.42 10.39 8.6 2.93
2 38 M Yes 8 20.9 8.39 9.6 0.89
3 53 M Yes 4 28.72 9.3 7.9 2.07
4 41 F Yes 4 26.81 8.2 7.8 1.88
5 29 M Yes 2 26.78 6.2 7.5 1.67
6 43 F Yes 2 27.55 10.83 8.7 1.93
7 61 M Yes 8 30.81 6.53 7.4 1.6
8 68 F Yes 6 21.2 6.21 8.4 0.97
9 40 M Yes 6 25.31 15.95 12.3 0.8
10 36 M Yes 1 25.14 11.59 10.2 1.03
11 54 F Yes 13 28.28 11.95 8.9 0.91
12 55 F Yes 14 25.04 8.27 9.7 0.91
13 57 M Yes 1 26.4 6.95 7.5 1.41
14 54 M Yes 15 32.35 7.6 7.9 1.5
15 45 F Yes 1 25 9.46 8.4 1.89
16 58 F Yes 10 22.91 8.97 9.7 1.08
17 57 F Yes 14 23.88 7.38 7.4 1.07
18 64 M Yes 13 32.81 8.3 8.4 2.09
Mean 50 7.5 26.68 9.03 8.68 1.48
(SD) (11) (5) (3.46) (2.44) (1.25) (0.58)
Group B: Long-standing patients having normal β cell function with insulin injection
19 52 M Yes 12 28.12 10.63 9.4 1.08
20 44 F Yes 9 24.2 10.64 8.1 0.96
21 60 F Yes 12 23.23 11.55 10.0 1.13
22 56 M Yes 11 28.37 12.19 7.5 1.19
23 46 M Yes 5 29.05 7.62 7.8 1.61
24 44 M Yes 2 31.35 10.99 8.5 1.96
25 40 M Yes 4 24.46 9.1 7.4 1.29
26 61 F Yes 13 30.47 11.03 8.8 1.53
27 64 F Yes 2 27.06 8.63 8.3 1.64
28 39 M Yes 11 28.09 10.94 9.8 1.84
29 47 M Yes 7 26.45 7.27 7.9 1.33
Mean 50 8 27.35 10.05 8.5 1.41
(SD) (9) (4) (2.59) (1.63) (0.9) (0.32)
Group C: Long-standing patients having impaired β cell function with insulin injection
30 66 F Yes 18 22.48 10.71 8.3 0.39
31 39 M Yes 3 19.83 8.0 13.2 0.45
32 55 F Yes 24 22.27 6.77 7.3 0.16
33 54 M Yes 15 25.69 8.56 8.5 0.59
34 49 F Yes 15 24.22 10.15 9.6 0.17
35 54 M Yes 11 27.72 8.02 8.9 0.56
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Table 1 Characteristics of the T2D subjects before treatment (Continued)
36 47 M Yes 15 24.28 9.18 11.1 0.19
Mean 52 14 23.78 8.77 9.56 0.36
(SD) (8) (6) (2.56) (1.36) (1.99) (0.19)
* The levels of 0.6 to approximately 3.4 ng/ml are the normal ranges for Chinese fasting C-peptide by radioimmunoassay (RIA). To convert C-peptide value to
nmol/L, multiply the ng/ml by 0.331.
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reduced at four weeks follow-up (Figure 1B). It sug-
gests that insulin sensitivity has been improved post-
treatment. Consistent with their improved β cell func-
tion, the median daily dose of metformin was decreased
from 33% to approximately 67%, and insulin was de-
creased to 35% at 12 weeks post-treatment.
Notably, we found that levels of fasting C-peptide were
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Figure 1 Improvement of metabolic control by stem cell educator the
(B) Analysis of insulin sensitivity by HOMA-IR C-peptide at four weeks post-
C-peptide levels in Group C T2D subjects with impaired islet β cell function
follow-up post-treatment with Stem Cell Educator therapy in Group C T2Dwith impaired islet β cell function (Group C, diabetic
duration 14 ± 6 years, n = 7, P = 0.0073) (Figure 1C).
Twelve weeks after receiving the Stem Cell Educator
therapy, fasting C-peptide levels reached normal phy-
siological levels and were maintained through the last
follow-up for this measure (56 weeks) (0.36 ± 0.19 ng/ml
at baseline vs 1.12 ± 0.33 ng/ml at one year post-
treatment, P = 0.00045, Figure 1C). The β-cell functional















































rapy. (A) Twelve-week follow-up of HbA1C levels in T2D subjects.
treatment with Stem Cell Educator therapy. (C) 56-week follow-up
. (D) Analysis of islet β cell function by HOMA-B C-peptide at 12-week
subjects.
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group C subjects after receiving Stem Cell Educator ther-
apy (Figure 1D). The data suggest that the restoration of
C-peptide may be associated with the regeneration of islet
β cells as we demonstrated in our previous work in type 1
diabetes [16,18].
Efficacy outcomes in correcting the immune dysfunction
To determine the molecular and cellular mechanisms
underlying the improvement of metabolic control, we
examined the effects of anti-inflammation and immune
modulation of Stem Cell Educator therapy in T2D.
We used ELISA to examine pro-inflammatory cytokines
IL-1, IL-6 and TNFα in the plasma, which are primarily
involved in insulin resistance and T2D [8,26]. We found



























































Figure 2 Anti-inflammatory effects of stem cell educator therapy. (A)
and four weeks after Stem Cell Educator therapy. (B) Flow analysis of intra-
at four weeks post-treatment. (C) Down-regulation percentage of CD86
Stem Cell Educator therapy. (D) Flow Analysis of CD4+CD25+Foxp3+ Tre
weeks post-treatment.in these long-standing T2D subjects and failed to show
changes after Stem Cell Educator therapy (P = 0.557,
P = 0.316, P = 0.603, respectively), probably because
metabolic inflammation is a chronic sub-degree inflam-
mation [8] and the plasma samples which were directly
collected from the blood of T2D patients, not from the
lipopolysaccharide (LPS)-activated monocytes of T2D
subjects [27]. Importantly, we found that anti-inflam-
matory and immune suppressive cytokine TGF-β1 was
markedly increased in the plasma of T2D subjects post-
treatment at four weeks relative to the baseline levels
(Figure 2A). However, IL-10 was unchanged in all partic-
ipants (P = 0.497). These findings suggest up-regulation
of TGF-β1 may be one of potential mechanisms contri-




























































Up-regulation of plasma levels of TGF-β1 in T2D patients at baseline
cellular cytokines demonstrating differential effects on key interleukins
+CD14+monocytes in T2D patients at baseline and four weeks after
gs demonstrating no change in the percentage of Tregs at four
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metry analysis, we examined interleukin-17 (IL-17, also
known as IL-17A) and Th1/Th2 immune response-
associated cytokines in the peripheral blood of T2D sub-
jects. IL-17A is a well-known pro-inflammatory cytokine
involved in autoimmune diseases. Importantly, mounting
evidence collected over the past decade indicates that the
etiology of T2D includes an autoimmune component that
initiates an inflammation affecting pancreatic islet β cells
[8,28-32], which provides new insight into the mechanism
and potential treatment of insulin resistance through im-
mune modulation. Recent clinical studies showed the in-
crease of circulating Th17 cells and IL-17 production in
T2D patients [33] and obese patients [34]. Additionally,
recent studies showed that the level of Th1-associated
cytokine IL-12 is increased in T2D subjects [35,36]. We
found that the production of IL-17, IL-12 and Th2-
associated cytokine IL-4 and IL-5 were all markedly de-
creased after Stem Cell Educator therapy (Figure 2B).
To explore the cellular mechanism underlying the
modulation on the Th1/Th2 immune responses, we fo-
cused on the changes of co-stimulating molecules CD80/
CD86 expressed on the monocytes/macrophages, the pro-
fessional antigen-presenting cells that play a key role in
the onset of chronic inflammation and obesity-associated
insulin resistance of T2D [6,37-40]. Flow results de-
monstrated that the percentage of CD86+CD14+ mono-
cytes was markedly decreased four weeks after treatment
(Figure 2C, P = 0.0212). There was no significant change
in the level of CD80+CD14+ monocytes (P = 0.13). The ra-
tio of CD86+CD14+ monocytes/CD80+CD14+ monocytes
was reduced from 3.86 ± 2.56 to 1.22 ± 0.48 (P = 0.01).
Further flow analysis of the ligands of CD80/CD86,
CD28/CTLA-4 expressed on lymphocytes revealed that
the expression of CTLA-4 was markedly increased four
weeks after receiving Stem Cell Educator therapy (0.51% ±
0.5 before treatment vs 1.98% ± 0.51 post-treatment,
P = 9.02E-05). However, flow analysis failed to show differ-
ences in the expression of co-stimulating molecule CD28
(69.98% ± 14.17 before treatment vs 61.5% ± 10.89 post-
treatment, P = 0.225). Additionally, we examined changes
in the CD4+CD25+Foxp3+ Tregs population after receiv-
ing Stem Cell Educator therapy. Flow analysis did not
identify any differences between baseline and 4 or 12
weeks post-treatment (Figure 2D, P = 0.689). Therefore,
these data suggest that Stem Cell Educator therapy may
modulate the Th1/Th2 immune responses through the
action of antigen-presenting cells monocytes rather than
Tregs.
In vitro mechanistic studies of the immune modulation of
CB-SCs on monocytes
To better understand the immune modulation of CB-SC
on monocytes, we performed in vitro co-cultureexperiments by using CD14+ monocytes purified from
human peripheral blood. The purified CD14+ monocytes
were co-cultured with CB-SCs at different ratios. We
found that there were strong reactions after adding the
CD14+ monocytes to CB-SCs (Figure 3A, bottom left
panel). Flow analysis demonstrated that co-culture with
CB-SCs for 18 hrs resulted in the significant apoptosis
of monocytes at the ratio 1:5 of CB-SC:monocytes
(Figure 3B). Correspondingly, both the cell viability and
attachment of CB-SCs were also affected in the presence
of apoptotic monocytes (Figure 3A, bottom left panel).
The cellular processes of CB-SCs were reduced in
length, but most were still attached to the bottom
(Figure 3A, bottom left panel). Interestingly, these im-
paired CB-SCs were restored after co-culture for 2 to 3
days; they continually expanded and became 90 to
approximately 100% confluence after 7 to 10 days
(Figure 3A, bottom right panel). Mechanistic studies re-
vealed that CB-SCs displayed the cellular inhibitor of
apoptosis protein (cIAP) 1 [41] that protects CB-SCs
against the cytotoxic effects of monocytes, allowing
them to survive and proliferate (Figure 3C). To further
explore the molecular mechanisms underlying the cyto-
toxic effects of monocytes on CB-SCs, we found that
CB-SCs expressed TNF-RII but not TNF-RI (Figure 3D).
Recombinant TNF showed cytotoxicity to CB-SCs at dif-
ferent doses (Figure 3E). Notably, CB-SCs pre-treated
with TNF-RII mAb (20 μg/ml) at a ratio of 1:10 could
markedly block the toxic action of monocytes and
protect 50% of CB-SCs with good cell viability and
morphology.
To further explore the immune modulation of CB-SCs
on monocytes, LPS-stimulated purified CD14+ monocytes
were co-cultured with CB-SCs. Real time PCR array
showed that co-culture with CB-SC could significantly
down-regulate numbers of LPS-stimulated, inflammation-
related genes, including chemokines, multiple cytokines
and matrix metallopeptidase, along with signaling pathway
molecule NF-κB (Figure 3F). These data clearly indicate
that in vitro co-culture with CB-SCs causes substantial
down-regulation of inflammation-associated gene expres-
sions in monocytes. Previous work showed that CB-SCs
function as immune modulators on lymphocytes via nitric
oxide (NO) production [15]. To confirm the action of NO
involved in the immune modulation of CB-SCs on mono-
cytes, the specific inducible nitric oxide synthase (iNOS)
inhibitor 1400W was applied to the co-culture system. The
data demonstrated that the inhibitory effects of CB-SC on
LPS-stimulated monocytes could be significantly reversed
in the presence of iNOS inhibitor 1400W (Figure 3F).
Interestingly, we found that blocking NO production in
CB-SCs could markedly increase the expressions of che-
mokine CCL20 and cytokines (for example, IL-1β, IL-6,
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Figure 3 In vitro study of the immune modulation of CB-SCs on monocytes. (A) Phase contrast microscopy shows the co-culture of CB-SC
with monocytes (bottom left panel) for 18 hrs. CB-SCs co-culture with lymphocytes (top right panel) served as the control. The impaired CB-SCs
after co-culture with monocytes were restored to expansion and became 90 to approximately 100% confluence after 7 to 10 days (bottom right).
Original magnification, × 100. (B) Apoptotic analysis of floating cells from the co-culture of CB-SCs with monocytes for 18 hrs. (C) Western
blotting shows the expression of the cellular inhibitor of apoptosis protein (cIAP) 1, not cIAP2, in four preparations of CB-SCs. (D) Western
blotting shows the expression of tumor necrosis factor receptor II (TNF-RII), not TNF-RI, in four preparations of CB-SCs. (E) TNFα suppresses the
proliferation of CB-SCs in a dose–response manner. Cell proliferation was evaluated using CyQUANTR Cell Proliferation Assay Kit [25]. (F) The
blocking experiment with iNOS inhibitor 1400W demonstrates that CB-SC-derived nitric oxide (NO) contributes to the immune modulation of
CB-SCs on monocytes. Monocytes were initially stimulated with lipopolysaccharide (LPS, 10 μg/ml) for 8 hrs, and then co-cultured with CB-SCs at
ratio 1:5 of CB-SCs:monocytes for 48 hrs in the presence or absence of 1400W (100 nM), followed by real time PCR analysis by using Human Th17
for Autoimmunity and Inflammation PCR Array kit (SABiosciences, Valencia, CA, USA).
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mune modulating and anti-inflammatory effects of CB-SCs
on monocytes.
Discussion
Insulin resistance is the hallmark of T2D. It is widely ac-
cepted that the inability of pancreatic β cells to functionin compensating for insulin resistance leads to the onset
of clinical diabetes. Persistent metabolic stresses inclu-
ding glucotoxicity, lipotoxicity, chronic metabolic in-
flammation, oxidative stress and endoplasmic reticulum
stress, cause progressive dysfunction of islet β cells and
finally lead to the cellular death and absolute shortage of
islet β cells in long-standing T2D subjects [42]. The
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therapeutic efficacy of Stem Cell Educator therapy in the
treatment of T2D. Insulin sensitivities were markedly in-
creased after receiving Stem Cell Educator therapy,
followed by the significant improvement of metabolic
controls in these long-standing T2D patients. Notably,
we found that T2D subjects in Group C (with the abso-
lute shortage of islet β cells) significantly improved
fasting C-peptide levels and β cell function. These data
indicate that Stem Cell Educator therapy may open up a
new avenue for the treatment of T2D.
Chronic inflammation of visceral adipose tissue (VAT)
is a major contributor to insulin resistance mediated by
adipose tissue-released adipokines (for example, IL-6,
TNFα, MCP-1 and resistin) [40,43]. Growing evidence
strongly demonstrated that an accumulation of macro-
phages by metabolic stress in the sites of affected tissues
(such as vasculature, adipose tissue, muscle and liver)
has emerged as a key process in the chronic metabolic-
stress-induced inflammation [44]. Monocytes/macrophages,
as one type of the professional antigen-presenting
cells, play an essential role in controlling the Th1/Th2
immune responses and maintaining homeostasis through
the co-stimulating molecules CD80/CD86 and released
cytokines. Persistent destructive effects of lipid influx
(for example, fatty acids and cholesterol) cause macro-
phage dysfunctions (including defective efferocytosis and
unresolved inflammation), resulting in recruitment and
activation of more monocytes/macrophages via MCP-1
and its receptor CCR2 [44]. Consequently, inflammatory
cytokines (for example, IL-6 and TNFα) produced by acti-
vated macrophages induce insulin resistance in major
metabolic tissues [26,44,45]. To prove the action of ma-
crophage in chronic inflammation and insulin resistance
in T2D, conditional depletion of CD11c+ macrophages or
inhibition of macrophage recruitment via MCP-1 knock-
out in obese mice resulted in a significant reduction in
systemic inflammation and an increase in insulin sensi-
tivity [46-48].
To clarify the modulation of Stem Cell Educator the-
rapy on blood monocytes, we found that expression of
CD86 and CD86+CD14+/CD80+CD14+ monocyte ratios
have been markedly changed after receiving Stem Cell
Educator therapy in T2D subjects. CD80 and CD86 are
two principal co-stimulating molecules expressed on
monocytes to skew the immune response toward Th1 or
Th2 differentiation through their ligands CD28/CTLA4
[49,50]. Due to the differences of expression levels and
binding affinity between CD80 and CD86 with their
ligands CD28/CTLA4, it is widely accepted that the
interaction of CD86 with CD28 dominates in co-
stimulating signals; conversely, the combination of
CD80 and CTLA4 governs negative signaling [49-52].
The normalization of the CD86+CD14+/CD80+CD14+monocyte ratio post-treatment may favor the immune
balance of Th1/Th2 responses in diabetic subjects.
Taken together with our in vitro study on the direct
interaction between CB-SCs and purified CD14+ mono-
cytes, these data indicate that restoration of monocyte
functions (such as the expression of CD86, cytokine
productions and chemokine productions) mainly con-
tributes to anti-inflammation and reversal of insulin re-
sistance following Stem Cell Educator therapy in T2D
subjects.
Increasing animal and clinical evidence demonstrate
multiple immune cells contributing to the inflammation-
induced insulin resistance in T2D, such as abnormali-
ties of lymphocytes (including T cells, B cells and Tregs
[53-57]), neutrophils [58], eosinophils [59], mast cells
[60] and dendritic cells (DCs) [61,62]. Specifically, B and
T lymphocytes have emerged as unexpected promoters
and controllers of insulin resistance [57]. These adaptive
immune cells infiltrate into the VAT, releasing cytokines
(IL-6 and TNFα) and recruiting more monocytes/
macrophages via MCP-1/CCR2 [44]. Finally, this obesity-
related inflammation leads to insulin resistance [57,63].
Thus, a major challenge for treatment of T2D is to iden-
tify therapeutic approaches that fundamentally correct in-
sulin resistance through targeting the dysfunctions of
multiple immune cells. The valuable lessons from inten-
sive research pressure over the past 25 years in T1D [11]
highlight the difficulties in overcoming these multiple im-
mune dysfunctions by utilizing conventional immune
therapy. Stem Cell Educator therapy functions as “an arti-
ficial thymus” that circulates a patient’s blood through a
blood cell separator [19], briefly co-cultures the patient’s
blood mononuclear cells (such as T cells, B cells, Tregs,
monocytes and neutrophils) with CB-SCs in vitro. During
the ex vivo co-culture in the device, these mononuclear
cells can be educated by the favorable microenvironment
created by CB-SCs through: 1) the action of an auto-
immune regulator (AIRE) expressed in CB-SCs [18]; 2)
the cell-cell contacting mechanism via the surface mol-
ecule programmed death ligand 1 (PD-L1) on CB-SCs
[15]; and 3) the soluble factors released by CB-SCs. Previ-
ous work [15] and current data indicate that CB-SC-de-
rived NO mainly contributes to the immune modulation
on T cells and monocytes. During the passage of mono-
cytes and other immune cells through the device, NO, as
a free radical released by CB-SCs, can quickly transmit
into their cellular membrane, without the aid of dedicated
transporters; 4) correcting the functional defects of regula-
tory T cells (Tregs) [16]; and 5) directly suppressing the
pathogenic T cell clones [17]. During this procedure, both
peripheral and infiltrated immune cells in VAT can be iso-
lated by a blood cell separator and treated by CB-SCs,
leading to the correction of chronic inflammation, the
restoration of the immune balance, and clinical
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insulin sensitivity. Additionally, TGF-β1 is a well-
recognized cytokine with a pleiotropic role in immune
modulation on multiple immune cells, such as the dif-
ferentiation and function of Th1/Th2 cells and Tregs,
as well as B cells, monocytes/macrophages, dendritic
cells, granulocytes and mast cells [64-66]. These im-
mune cells are involved in the inflammation-induced
insulin resistance in T2D [53-62]. Therefore, the up-
regulation of TGF-β1 level in peripheral blood of T2D
subjects is another major mechanism underlying the
immune modulation after receiving Stem Cell educator
therapy.
During the procedure of Stem Cell Educator therapy,
the mononuclear cells circulating in a patient’s blood are
collected by a blood cell separator. Additionally, patients
are required to move their hips, legs and turn to one
side every 15 to 30 minutes during the treatment, in
order to mobilize their immune cells from peripheral tis-
sues (including adipose tissues) and organs entering into
the blood circulation to be processed by a blood cell sep-
arator. Thus, the immune cells both in peripheral blood
and in tissues can be isolated by a blood cell separator
and treated by CB-SCs. The full blood volume is pro-
cessed approximately twice during Stem Cell Educator
therapy (approximately 10,000 ml whole blood) [18],
which ensures a comprehensive approach to modulating
essentially all circulating immune cells to address mul-
tiple immune dysfunctions and overcome global insulin
resistance resulting from a variety of reasons. No other
current medications and/or other approaches have yet
been shown to achieve this unique therapy success.
There are some pathogenic immune cells remaining in
tissues and lymph nodes which fail to enter into the
blood circulation during the procedure and may escape
from the treatment by CB-SCs. These immune cells may
migrate into the blood circulation and decrease the
therapeutic effectiveness. Therefore, T2D subjects may
need additional treatment six to nine months later after
receiving the first treatment; however, this is yet to be
explored in the phase 3 clinical trial.
We observed that the improvement of islet β cell func-
tion (C-peptide levels) progresses slowly over weeks after
receiving Stem Cell Educator therapy, not disappearing
with the progression of time. We reported similar data
in previous T1D trials [18,19]. If Stem Cell Educator
therapy only temporarily corrects the immune dysfunc-
tions, the clinical efficacy in metabolic control should
disappear soon after receiving Stem Cell Educator ther-
apy, because of the short lifespans of most immune cells,
(for example, 5.4 days for neutrophils [67], 3 months for
lymphocytes, 1 to 3 days for bone marrow-derived
monocytes existing in blood and then migrating into tis-
sues). Previous work demonstrated that CB-SCs showedthe marked modulation of Th1-Th2-Th3 cell-related
genes, including multiple cytokines and their receptors,
chemokines and their receptors, cell surface molecules,
along with signaling pathway molecules and transcrip-
tion factors, as indicated by quantitative real time PCR
array [16]. Due to these fundamental immune modula-
tions and induction of immune balance [19], this trial in-
dicates that a single treatment with Stem Cell Educator
therapy can give rise to long-lasting reversal of immune
dysfunctions and improvement of insulin sensitivity in
long-standing T2D subjects.
Conclusions
The epidemic of diabetes is creating an enormous im-
pact on the global economy, as well as on the health of
humans. Overcoming insulin resistance is a major target
for the treatment of T2D, and mounting evidence points
to the involvement of multiple immune dysfunctions in
T2D [3,37,40]. Monocytes/macrophages act as key pla-
yers contributing to these chronic inflammations and
leading to insulin resistance in T2D [6,33,37,39,40]. The
current phase 1/phase 2 study demonstrates that Stem
Cell Educator therapy can control the immune dys-
functions and restore the immune balance through the
modulation of monocytes/macrophages and other im-
mune cells, both in peripheral blood and in tissues, lead-
ing to a long-lasting reversal of insulin resistance and a
significant improvement in insulin sensitivity and meta-
bolic control in long-standing T2D subjects. These fin-
dings are subject to further investigation in large-scale,
multi-center clinical trials. This novel approach holds
great promise for improving treatment and finding a
cure for diabetes, specifically for early-stage diabetics.
The advantages of Stem Cell Educator therapy may help
diabetics to cope with diabetes-associated complications
and improve their quality of life.
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